Values of MMP-2 and MMP-9 in Tumor Tissue of Basal-Like Breast Cancer Patients

Cell Biochemistry and Biophysics

Volumn 68, Issue 1, 2014, Pages 143-152

  Radenkovic, Sandra ^a   Konjevic, Gordana ^a,b   Jurisic, Vladimir ^c   Karadzic, Katarina ^a   Nikitovic, Marina ^a,b   Gopcevic, Kristina ^b  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

Basal like breast cancer; Clinicopathological markers; MMP 2; MMP 9; Tumor tissue

Indexed keywords

ENZYME PRECURSOR; GELATINASE A; GELATINASE B; PRO MATRIX METALLOPROTEINASE 9; PRO-MATRIX METALLOPROTEINASE 9; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER STAGING; ENZYMOLOGY; FEMALE; HUMAN; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ENZYME PRECURSORS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 84891625671     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9701-x     Document Type: Article

References (32)

1. Woessner, J. F., Jr. (1991). Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB Journal, 1991(5), 2145-2154.
2. Hofmann, U. B., Houben, R., Brocker, E. B., & Becker, J. C. (2005). Role of matrix metalloproteinases in melanoma cell invasion. Biochimie, 87, 307-314.
3. Liu, S. C., Yang, S. F., Yeh, K. T., Yeh, C. M., Chiou, H. L., Lee, C. Y., et al. (2006). Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer. Clinica Chimica Acta, 371(1-2), 92-96.
4. Shah, F. D., Shukla, S. N., Shah, P. M., Shukla, H. K., & Patel, P. S. (2009). Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian Journal of Cancer, 46, 194-202.
5. Remacle, A. G., Noel, A., Duggan, C., McDermott, E., O'Higgins, N., Foidart, J. M., et al. (1998). Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. British Journal of Cancer, 77(6), 926-931.
6. Li, H. C., Cao, D. C., Liu, Y., Hou, Y. F., Wu, J., Lu, J. S., et al. (2004). Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Research and Treatment, 88(1), 75-85.
7. Hanemaaijer, R., Verheijen, J. H., Maguire, T. M., Visser, H., Toet, K., McDermott, E., et al. (2000). Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. International Journal of Cancer, 86(2), 204-207.
8. Jinga, D. C., Blidaru, A., Condrea, I., Ardeleanu, C., Dragomir, C., Szegli, G., et al. (2006). MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: Correlations with prognostic factors. Journal of Cellular and Molecular Medicine, 10(2), 499-510.
9. Sullu, Y., Demirag, G. G., Yildirim, A., Karagoz, F., & Kandemir, B. (2011). Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. Pathology, Research and Practice, 207(12), 747-753.
10. Pellikainen, J. M., Ropponen, K. M., Kataja, V. V., Kellokoski, J. K., Eskelinen, M. J., & Kosma, V. M. (2004). Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clinical Cancer Research, 10, 7621-7628.
11. Konecny, G., Untch, M., Arboleda, J., Wilson, C., Kahlert, S., Boettcher, B., et al. (2001). HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clinical Cancer Research, 7(8), 2448-2457.
12. Weigelt, B., & Reis-Filho, J. S. (2009). Histological and molecular types of breast cancer: Is there a unifying taxonomy? Nature Reviews Clinical Oncology, 6(12), 718-730.
13. Abd El-Rehim, D. M., Pinder, S. E., Paish, C. E., Bell, J., Blamey, R. W., Robertson, J. F., et al. (2004). Expression of luminal and basal cytokeratins in human breast carcinoma. Journal of Pathology, 203(2), 661-671.
14. Reis-Filho, J. S., & Tutt, A. N. (2008). Triple negative tumours: A critical review. Histopathology, 52(1), 108-118.
15. Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 1976(72), 248-254.
16. Stetler-Stevenson, W. G. (1990). Type IV collagenases in tumor invasion and metastasis. Cancer and Metastasis Reviews, 9(4), 289-303.
17. Kleiner, D. E., & Stetler-Stevenson, W. G. (1994). Quantative zymography detection of picogram quantities of gelatinases. Analytical Biochemistry, 218(2), 325-329.
18. Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 1970(227), 680-685.
19. Lavasani, M. A., & Moinfar, F. (2012). Molecular classification of breast carcinomas with particular emphasis on "basal-like" carcinoma: a critical review. Journal of Biophotonics, 5(4), 345-366.
20. Stankovic, S., Konjevic, G., Gopcevic, K., Jovic, V., Inic, M., & Jurisic, V. (2010). Activity of MMP-2 and MMP-9 in sera of breast cancer patients. Pathology, Research and Practice, 206(4), 241-247.
21. Zucker, S., Hymowitz, M., Conner, C., Zarrabi, H. M., Hurewitz, A. N., Matrisian, L., et al. (1999). Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Annals of the New York Academy of Sciences, 878, 212-227.
22. Jezierska, A., & Motyl, T. (2009). Matrix metalloproteinase-2 involvement in breast cancer progression: A mini-review. Medical Science Monitor, 15(2), 32-40.
23. Talvensari-Mattila, A., Pakko, P., Blanco-Sequeiros, G., & Turpeenniemi-Hujanen, T. (2001). Matrix metalloproteinases-2 is associated with the risk for a relapse in postmenopausal patients with node positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Research and Treatment, 65(1), 55-61.
24. Hirvonen, R., Talvensari-Mattila, A., Pakko, P., & Turpeenniemi-Hujanen, T. (2003). Matrix metalloproteinases-2 (MMP-2) in T (1-2) N0 breast carcinoma. Breast Cancer Research and Treatment, 77(1), 85-91.
25. Ali, H. R., Dawson, S. J., Blows, F. M., Provenzano, E., Pharoah, P. D., & Caldas, C. (2011). Cancer stem cell markers in breast cancer: Pathological, clinical and prognostic significance. Breast Cancer Research, 13(6), R118.
26. Talvensaari-Mattila, A., Paakko, P., & Turpeenniemi-Hujanen, T. (2003). Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. British Journal of Cancer, 89, 1270-1275.
27. Rahko, E., Jukkola, A., Melkko, J., Paavo, P., Bloigu, R., Talvensaari-Mattila, A., et al. (2004). Matrix metalloproteinase-9 (MMP-9) immunoreactive protein has modest prognostic value in locally advanced breast carcinoma patients treated with an adjuvant antiestrogen therapy. Anticancer Research, 24(6), 4247-4253.
28. Banerjee, S., & Smith, I. E. (2010). Management of small HER2-positive breast cancers. Lancet Oncology, 11(12), 1193-1199.
29. Fulford, L. G., Reis-Filho, J. S., Ryder, K., Jones, C., Gillett, C. E., Hanby, A., et al. (2007). Basal-like grade III invasive ductal carcinoma of the breast: Patterns of metastasis and long-term survival. Breast Cancer Research, 9(1), R4.
30. Hornebeck, W., Emonard, H., Monboisse, J. C., & Bellon, G. (2002). Matrix-directed regulation of pericellular proteolysis and tumor progression. Seminars in Cancer Biology, 12(3), 231-241.
31. Guo, W., & Giancotti, F. G. (2004). Integrin signalling during tumour progression. Nature Reviews Molecular Cell Biology, 5, 816-826.
32. Bourboulia, D., & Stetler-Stevenson, W. G. (2010). Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Seminars in Cancer Biology, 20(3), 161-168.